Cardiff Oncology Beats Expectations in Full Year 2024 Earnings
Cardiff Oncology's full year 2024 earnings have exceeded analyst estimates, with a net loss of US$45.5m and a loss per share of US$0.95, wider than the previous year's loss of US$0.93. The company's revenue surpassed expectations by 12%, beating forecasts for growth in the biotechs industry in the US. Looking ahead, Cardiff Oncology's revenue is forecast to grow at an average rate of 52% per annum over the next three years.
- This unexpected beat could be seen as a bullish sign for the biotech sector, potentially signaling that investors are becoming more optimistic about the prospects of companies like Cardiff Oncology.
- However, despite this short-term success, how will the company's high-growth ambitions impact its ability to deliver sustainable returns for shareholders in the long term?